MicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesis

BBA Clinical

Volumn 3, Issue 1, 2015, Pages 79-89

  Song, Jinsoo ^a   Jin, Eun Heui ^a   Kim, Dongkyun ^a   Kim, Keun Young ^a   Chun, Churl Hong ^a   Jin, Eun Jung ^a  

^a Wonkwang University   (South Korea)

Author keywords

Apoptosis; HDAC 4; Human chondrocytes; MiR 222; MMP 13; OA chondrocytes

Indexed keywords

COLLAGENASE 3; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; INTERLEUKIN 1BETA; LENTIVIRUS VECTOR; MESSENGER RNA; MICRORNA 101; MICRORNA 130A; MICRORNA 146A; MICRORNA 155; MICRORNA 15A; MICRORNA 15B; MICRORNA 210; MICRORNA 222; MICRORNA 30A; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS ASSAY; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CARTILAGE DEGENERATION; CONTROLLED STUDY; DEACETYLATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MALE; MOUSE; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; WESTERN BLOTTING;

EID: 84937118273     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2014.11.009     Document Type: Article

References (58)

1. Tchetina E.V., Squires G., Poole A.R. Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions. J. Rheumatol. 2005, 32:876-886.
2. Kronenberg H.M. Developmental regulation of the growth plate. Nature 2003, 423:332-336.
3. Loeser R.F. Molecular mechanisms of cartilage destruction: mechanics, inflammatory mediators, and aging collide. Arthritis Rheum. 2006, 54:1357-1360.
4. Bau B., Gebhard P.M., Haag J., Knorr T., Bartnik E., Aigner T. Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum. 2002, 46:2648-2657.
5. Neuhold L.A., Killar L., Zhao W., Sung M.L., Warner L., Kulik J., Turner J., Wu W., Billinghurst C., Meijers T., et al. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J. Clin. Invest. 2001, 107:35-44.
6. Little C.B., Barai A., Burkhardt D., Smith S.M., Fosang A.J., Werb Z., Shah M., Thompson E.W. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum. 2009, 60:3723-3733.
7. Nebbioso A., Dell'Aversana C., Bugge A., Sarno R., Valente S., Rotili D., Manzo F., Teti D., Mandrup S., Ciana P., Mol Endocrinol J., et al. HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. J. Mol. Endocrinol. 2010, 45:219-228.
8. Tou L., Liu Q., Shivdasani R.A. Regulation of mammalian epithelial differentiation and intestine development by class I histone deacetylases. Mol. Cell. Biol. 2004, 24:3132-3139.
9. Halsall J., Gupta V., O'Neill L.P., Turner B.M., Nightingale K.P. Genes are often sheltered from the global histone hyperacetylation induced by HDAC inhibitors. PLoS One 2012, 7:e33453.
10. Lin H.S., Hu C.Y., Chan H.Y., Liew Y.Y., Huang H.P., Lepescheux L., Bastianelli E., Baron R., Rawadi G., Clément-Lacroix P. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 2007, 150:862-872.
11. Villar-Garea A., Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int. J. Cancer 2004, 112:171-178.
12. Blanchard F., Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?. Drug Discov. Today 2005, 10:197-204.
13. Nishida K., Komiyama T., Miyazawa S., Shen Z.N., Furumatsu T., Doi H., Yoshida A., Yamana J., Yamamura M., Ninomiya Y., et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 2004, 50:3365-3376.
14. Flynt A.S., Lai E.C. Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat. Rev. Genet. 2008, 9:831-842.
15. Ceman S., Saugstad J. MicroRNAs: meta-controllers of gene expression in synaptic activity emerge as genetic and diagnostic markers of human disease. Pharmacol. Ther. 2011, 130:26-37.
16. Wu H., Ye C., Ramirez D., Manjunath N. Alternative processing of primary microRNA transcripts by Drosha generates 5' end variation of mature microRNA. PLoS One 2009, 27:e7566.
17. Oglesby I.K., McElvaney N.G., Greene C.M. MicroRNAs in inflammatory lung disease-master regulators or target practice?. Respir. Res. 2010, 11:148.
18. Ambros V. MicroRNAs and developmental timing. Curr. Opin. Genet. Dev. 2011, 21:511-517.
19. Hinton A., Hunter S., Reyes G., Fogel G.B., King C.C. From pluripotency to islets: miRNAs as critical regulators of human cellular differentiation. Adv. Genet. 2012, 79:1-34.
20. Jovanovic M., Hengartner M.O. miRNAs and apoptosis: RNAs to die for. Oncogene 2006, 25:6176-6187.
21. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
22. Xu Q., Seeger F.H., Castillo J., Iekushi K., Boon R.A., Farcas R., Manavski Y., Li Y.G., Assmus B., Zeiher A.M., et al. Micro-RNA-34a contributes to the impaired function of bone marrow-derived mononuclear cells from patients with cardiovascular disease. J. Am. Coll. Cardiol. 2012, 59:2107-2117.
23. Ropers H.H. X-linked mental retardation: many genes for a complex disorder. Curr. Opin. Genet. Dev. 2006, 16:260-269.
24. Liu C.J. MicroRNAs in skeletogenesis. Front. Biosci. 2009, 14:2757-2764.
25. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., Harano T., Yatabe Y., Nagino M., Nimura Y., et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64:3753-3756.
26. Goldring M.B., Martel-Pelletier J., Abramson S.B. Osteoarthritis, an inflammatory disease: potential implications for the selection of new therapeutic targets. Arthritis Rheum. 2001, 44:1237-1247.
27. Goldring M.B. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect. Tissue Res. 1999, 40:1-11.
28. Lin H.Y., Chen C.S., Lin S.P., Weng J.R., Chen C.S. Targeting histone deacetylase in cancer therapy. Med. Res. Rev. 2006, 26:397-413.
29. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002, 1:287-299.
30. Kortenhorst M.S., Carducci M.A., Shabbeer S. Acetylation and histone deacetylase inhibitors in cancer. Cell. Oncol. 2006, 28:191-222.
31. Nasu Y., Nishida K., Miyazawa S., Komiyama T., Kadota Y., Abe N., Yoshida A., Hirohata S., Ohtsuka A., Ozaki T. Trichostatin, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthr. Cartil. 2008, 16:723-732.
32. Chabane N., Zayed N., Afif H., Mfuna-Endam L., Benderdour M., Boileau C., Martel-Pelletier J., Pelletier J.P., Duval N., Fahmi H. Histone deacetylase inhibitors suppress interleukin-1beta-induced nitric oxide and prostaglandin E2 production in human chondrocytes. Osteoarthritis Cartilage 2008, 16:1267-1274.
33. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
34. Zemmyo M., Meharra E.J., Kühn K., Creighton-Achermann L., Lotz M. Accelerated, aging-dependent development of osteoarthritis in alpha1 integrin-deficient mice. Arthritis Rheum. 2003, 48:2873-2880.
35. Koskinen A., Vuolteenaho K., Nieminen R., Moilanen T., Moilanen E. Leptin enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients. Clin. Exp. Rheumatol. 2011, 29:57-64.
36. Young D.A., Lakey R.L., Pennington C.J., Jones D., Kevorkian L., Edwards D.R., Cawston T.E., Clark I.M. Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res. Ther. 2005, 7:R503-R512.
37. Estella C., Herrer I., Atkinson S.P., Quiñonero A., Martínez S., Pellicer A., Simón C. Inhibition of histone deacetylase activity in human endometrial stromal cells promotes extracellular matrix remodelling and limits embryo invasion. PLoS One 2012, 7:e30508.
38. Liu L.T., Chang H.C., Chiang L.C., Hung W.C. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res. 2003, 63:3069-3072.
39. Venugopal B., Evans T.R. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr. Med. Chem. 2011, 18:1658-1671.
40. Wang X., Song Y., Jacobi J.L., Tuan R.S. Inhibition of histone deacetylases antagonized FGF2 and IL-1beta effects on MMP expression in human articular chondrocytes. Growth Factors 2009, 27:40-49.
41. Chen W.P., Bao J.P., Tang J.L., Hu P.F., Wu L.D. Trichostatin A inhibits expression of cathepsins in experimental osteoarthritis. Rheumatol. Int. 2011, 31:1325-1331.
42. Furumatsu T., Tsuda M., Yoshida K., Taniguchi N., Ito T., Hashimoto M., Ito T., Asahara H. Sox9 and p300 cooperatively regulate chromatin-mediated transcription. J. Biol. Chem. 2005, 280:35203-35208.
43. Hong S., Derfoul A., Pereira-Mouries L., Hall D.J. A novel domain in histone deacetylase 1 and 2 mediates repression of cartilage-specific genes in human chondrocytes. FASEB J 2009, 23:3539-3552.
44. Higashiyama R., Miyaki S., Yamashita S., Yoshitaka T., Lindman G., Ito Y., Sasho T., Takahashi K., Lotz M., Asahara H. Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis. Mod. Rheumatol. 2010, 20:11-17.
45. Fabbri M., Garzon R., Cimmino A., Liu Z., Zanesi N., Callegari E., Liu S., Alder H., Costinean S., Fernandez-Cymering C., et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15805-15810.
46. Garzon R., Liu S., Fabbri M., Liu Z., Heaphy C.E., Callegari E., Schwind S., Pang J., Yu J., Muthusamy N., et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009, 113:6411-6418.
47. Noonan E.J., Place R.F., Pookot D., Basak S., Whitson J.M., Hirata H., Giardina C., Dahiya R. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009, 28:1714-1724.
48. Roccaro A.M., Sacco A., Jia X., Azab A.K., Maiso P., Ngo H.T., Azab F., Runnels J., Quang P., Ghobrial I.M. microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood 2010, 116:1506-1514.
49. Iliopoulos D., Malizos K.N., Oikonomou P., Tsezou A. Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS One 2008, 3:e3740.
50. Tuddenham L., Wheeler G., Ntounia-Fousara S., Waters J., Hajihosseini M.K., Clark I., Dalmay T. The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells. FEBS Lett. 2006, 580:4214-4217.
51. Shimizu E., Selvamurugan N., Westendorf J.J., Olson E.N., Partridge N.C. HDAC4 represses matrix metalloproteinase-13 transcription in osteoblastic cells, and parathyroid hormone controls this repression. J. Biol. Chem. 2010, 285:9616-9626.
52. Pais H., Nicolas F.E., Soond S.M., Swingler T.E., Clark I.M., Chantry A., Moulton V., Dalmay T. Analyzing mRNA expression identifies Smad3 as a microRNA-140 target regulated only at protein level. RNA 2010, 16:489-494.
53. Valdes A.M., Spector T.D., Tamm A., Kisand K., Doherty S.A., Dennison E.M., Mangino M., Tamm A., Kerna I., Hart D.J., et al. Genetic variation in the SMAD3 gene is associated with hip and knee osteoarthritis. Arthritis Rheum. 2010, 62:2347-2352.
54. Miyaki S., Sato T., Inoue A., Otsuki S., Ito Y., Yokoyama S., Kato Y., Takemoto F., Nakasa T., Yamashita S., et al. MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev. 2010, 24:1173-1185.
55. Glasson S.S., Askew R., Sheppard B., Carito B., Blanchet T., Ma H.L., Flannery C.R., Peluso D., Kanki K., Yang Z., et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005, 434:644-648.
56. Tardif G., Hum D., Pelletier J.P., Duval N., Martel-Pelletier J. Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. BMC Musculoskelet. Disord. 2009, 10:148.
57. Barter M.J., Bui C., Young D.A. Epigenetic mechanisms in cartilage and osteoarthritis: DNA methylation, histone modifications and microRNAs. Osteoarthritis Cartilage 2012, 339-349.
58. Chang J., Varghese D.S., Gillam M.C., Peyton M., Modi B., Schiltz R.L., Girard L., Martinez E.D. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. Br. J. Cancer 2012, 106:116-125.